Full history for every metric is available with a Kvantra account
Avinger, Inc. (AVGR)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 8 | 9 | 9 | 10 | 8 | 8 | 7 |
| Operating profit | $m | -17 | -17 | |||||
| Net profit | $m | -28 | -20 | -20 | -21 | -17 | -18 | -19 |
| EPS reported | $ | -23.31 | -12.15 | |||||
| Operating cashflow per share | $ | -18.36 | -18.36 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -18.37 | -18.37 | |||||
| Free cash flow | $m | -14 | -15 | |||||
| Net debt | $m | 9 | -2 | |||||
| Book value equity | $m | -6 | 4 | |||||
| Book value per share | $ | -7.89 | 1.74 | |||||
| Number of shares | m | 0.79 | 2.22 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.34 | 0.39 | |||||
| P/S LTM | x | 0.28 | 0.21 | |||||
| P/FCF LTM | x | -0.15 | -0.10 | |||||
| EV/EBITDA LTM | x | -0.75 | 0.01 | |||||
| EV/Sales LTM | x | 1.60 | -0.03 | |||||
| Earnings Yield LTM | % | -860.07% | -4917.3% | |||||
| FCF Yield | % | -677.92% | -960.30% | |||||
| Quality | ||||||||
| ROE | % | 295.39% | 1782.1% | |||||
| ROIC | % | -168.63% | -168.63% | |||||
| Operating margin | % | -217.39% | -217.39% | |||||
| Gross margin | % | 26.18% | 26.18% | |||||
| FCF/Sales | % | -188.71% | -188.71% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -7.51% | -6.26% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | -0.32% | |||||
| FCF/Debt | x | -0.94 | -2.60 | |||||
| Net Debt/EBITDA | x | -0.62 | -0.62 | |||||
| EBIT/Net interest | x | -9.68 | -9.68 | |||||
| Net debt/market cap | % | 423.37% | -114.36% | |||||
| Net debt/Equity | x | -1.45 | -0.45 | |||||
| Gross debt/equity | x | -2.48 | 1.44 | |||||
Company overview
Avinger, Inc. is a commercial-stage medical technology firm that develops, manufactures, and markets sophisticated image-guided, catheter-based systems. These devices are utilized by physicians both domestically and internationally to treat patients suffering from Peripheral Arterial Disease (PAD). Central to Avinger's offerings is its proprietary lumivascular platform. This innovative technology integrates Optical Coherence Tomography (OCT) visualization directly into interventional catheters, providing real-time, intravascular imaging to guide doctors during PAD procedures. The company's lumivascular product suite includes the Lightbox imaging consoles, as well as the Ocelot family of catheters, which are specifically designed to help physicians penetrate complete arterial blockages. Additionally, the Pantheris is an image-guided atherectomy device enabling precise removal of plaque from affected arteries. Avinger also offers its earlier-generation Chronic Total Occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2. These employ a unique rotational spinning technique, allowing physicians to switch between passive and active modes when navigating difficult CTOs. Furthermore, the company is developing IMAGE-BTK, a specialized solution for treating PAD lesions located below-the-knee. Avinger's advanced medical devices are sold to a specialized clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists. The company was founded in 2007 and is headquartered in Redwood City, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Avinger, Inc. (AVGR)
Avinger, Inc. is a commercial-stage medical technology firm that develops, manufactures, and markets sophisticated image-guided, catheter-based systems. These devices are utilized by physicians both domestically and internationally to treat patients suffering from Peripheral Arterial Disease (PAD). Central to Avinger's offerings is its proprietary lumivascular platform. This innovative technology integrates Optical Coherence Tomography (OCT) visualization directly into interventional catheters, providing real-time, intravascular imaging to guide doctors during PAD procedures. The company's lumivascular product suite includes the Lightbox imaging consoles, as well as the Ocelot family of catheters, which are specifically designed to help physicians penetrate complete arterial blockages. Additionally, the Pantheris is an image-guided atherectomy device enabling precise removal of plaque from affected arteries. Avinger also offers its earlier-generation Chronic Total Occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2. These employ a unique rotational spinning technique, allowing physicians to switch between passive and active modes when navigating difficult CTOs. Furthermore, the company is developing IMAGE-BTK, a specialized solution for treating PAD lesions located below-the-knee. Avinger's advanced medical devices are sold to a specialized clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists. The company was founded in 2007 and is headquartered in Redwood City, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free